The U.S. Food and Drug Administration (FDA) Office of Dietary Supplement Programs (ODSP) is signaling a renewed focus on regulatory modernization, enhanced compliance, and a stronger partnership with the dietary supplement industry. Hellen Oketch-Rabah, Ph.D., deputy director of the ODSP, articulated these key priorities during her keynote address at the American Herbal Products Association’s (AHPA) 2026 Botanical Congress, held in Portland, Oregon. The address comes at a pivotal time, with recent personnel shifts within the FDA prompting close observation from supplement manufacturers, particularly those specializing in botanical products, regarding potential impacts on their operations in the coming year.
Dr. Oketch-Rabah, a seasoned professional with extensive experience in botanical and supplement safety, highlighted the agency’s commitment to transparency and collaboration. Her background, which includes roles at the U.S. Pharmacopeia and as a principal scientist at Herb Pharm, a dietary supplement company, positions her as an informed voice within the regulatory landscape. Graham Rigby, president and CEO of AHPA, introduced Dr. Oketch-Rabah, noting her deep understanding of the industry, and her address was widely anticipated to provide crucial insights into the FDA’s forward-looking strategy.
Strengthening Regulatory Frameworks: NDI and Compliance
A central theme of Dr. Oketch-Rabah’s presentation was the agency’s dedication to fortifying the regulatory framework for dietary supplements, with a particular emphasis on New Dietary Ingredient (NDI) notifications. The FDA aims to enhance clarity and efficiency surrounding NDI regulations, a critical component for bringing new ingredients to the market. This initiative includes the advancement of related guidances, such as the publication of comprehensive guidance on the safety and identity requirements for NDI notifications. The agency intends to provide clearer parameters on when an NDI notification is indeed necessary, aiming to reduce ambiguity and streamline the submission process for manufacturers.
The importance of robust NDI submissions cannot be overstated. A well-prepared NDI notification provides the FDA with critical data to assess the safety of a new dietary ingredient before it enters the market. Historically, the absence or inadequacy of such information has led to regulatory scrutiny and, in some cases, product recalls. By clarifying these requirements, the FDA seeks to ensure that only safe and properly documented ingredients are available to consumers, while simultaneously facilitating innovation within the industry. Industry stakeholders have often cited the complexity and perceived opacity of NDI requirements as a significant hurdle. The FDA’s stated intention to publish clearer guidance suggests a move towards greater predictability and support for responsible product development.
Enhancing Industry Flexibility and Reducing Regulatory Burden
Beyond strengthening specific regulations, Dr. Oketch-Rabah emphasized the FDA’s objective to foster greater flexibility and alleviate the regulatory burden on the supplement industry. A notable example cited was the Dietary Supplement Health and Education Act of 1994 (DSHEA). Under DSHEA, the FDA requires a specific disclaimer to be placed on all panels of a product label. Recognizing the practical challenges and often significant costs associated with adhering to this requirement across multiple label panels, the FDA is working towards enforcing that the disclaimer be placed on only one panel.
"We want to make this change permanent," Dr. Oketch-Rabah stated, indicating a commitment to codifying this more practical approach. This adjustment, while seemingly minor, can have a substantial impact on label design, manufacturing processes, and overall cost-efficiency for supplement companies. It reflects an acknowledgement by the agency that regulatory requirements should be practical and achievable without compromising consumer safety or product information. Industry associations have long advocated for such pragmatic adjustments, arguing that overly stringent labeling requirements can divert resources from more critical areas of compliance and product quality.
Improving Agency Efficiency and Resource Allocation
Dr. Oketch-Rabah also addressed internal agency initiatives aimed at improving operational efficiencies. These efforts are designed to enable the FDA to better allocate its resources to areas where they are most needed and where the potential for risk is greatest. This includes streamlining internal processes and leveraging technology to enhance the agency’s oversight capabilities.
The deputy director pointed out that finished dietary supplement specifications consistently represent the area with the highest number of approved and supported warning letters. This statistic underscores the critical importance of product specifications in ensuring quality and safety. Dr. Oketch-Rabah reiterated the significance of well-defined specifications, describing them as the "central, defining characteristic of a product." She emphasized that establishing robust specifications is fundamental to building quality directly into the product from its inception. Clear and comprehensive specifications help manufacturers define the identity, purity, strength, and composition of their products, providing a crucial benchmark for quality control and regulatory compliance. Inadequate specifications can lead to product variability, contamination, or mislabeling, all of which pose risks to consumer health and erode public trust.
Leveraging Technology for Modernized Oversight
In a move to further enhance efficiency and gain a more comprehensive understanding of the marketplace, the ODSP plans to leverage Artificial Intelligence (AI) and data analytics to modernize its oversight efforts. Dr. Oketch-Rabah explained that these technological advancements will provide the agency with a more robust and insightful view of products currently available to consumers.
The integration of AI and data analytics into regulatory oversight represents a significant shift towards a more proactive and data-driven approach. By analyzing vast datasets, the FDA can potentially identify emerging trends, potential risks, and areas of non-compliance more effectively. This could lead to earlier interventions and a more targeted allocation of investigative resources. The use of AI can also assist in pattern recognition, anomaly detection, and risk assessment, enabling the agency to move beyond reactive enforcement to a more predictive and preventive model. This aligns with a broader trend in regulatory bodies globally to embrace technological innovation to manage complex and rapidly evolving industries.
A Call for Collaborative Partnership
Concluding her address, Dr. Oketch-Rabah strongly emphasized the ODSP’s desire for continuous dialogue and feedback from the industry. She reiterated the agency’s belief that collaborative efforts are essential for developing and maintaining a modern and effective framework for dietary supplements.
"We believe in a collaborative partnership and a proactive relationship," Dr. Oketch-Rabah stated. "We don’t know what all is out in the industry, so it is important to work in partnership." This sentiment underscores a strategic shift towards a more engaged and less adversarial relationship between the regulator and the regulated. By actively seeking input from industry stakeholders, the FDA aims to gain a more nuanced understanding of the challenges and opportunities present in the market. This collaborative approach is crucial for developing regulations that are both effective in protecting public health and practical for businesses to implement.
Context and Implications of the AHPA Botanical Congress
The American Herbal Products Association (AHPA) is the national trade association representing the herbal product industry. Its annual Botanical Congress serves as a critical forum for manufacturers, suppliers, regulators, and researchers to discuss the latest developments, challenges, and opportunities within the botanical sector. The 2026 Congress, therefore, provided an opportune moment for the FDA to communicate its strategic direction directly to a key segment of the industry it oversees.
The timing of Dr. Oketch-Rabah’s address is particularly relevant given the dynamic nature of the dietary supplement market. Factors such as evolving consumer demand for natural and plant-based products, advancements in ingredient sourcing and processing, and the increasing complexity of global supply chains all contribute to an environment where clear and adaptable regulatory guidance is paramount. The FDA’s stated commitment to modernization and collaboration suggests a recognition of these market realities and a desire to foster an environment that supports both innovation and consumer safety.
Background on Hellen Oketch-Rabah and the ODSP
Hellen Oketch-Rabah, Ph.D., has a distinguished career dedicated to food safety and dietary supplements. Her current position as deputy director within the ODSP places her at the forefront of shaping the agency’s policies and strategies for the dietary supplement industry. The ODSP itself is a critical component of the FDA’s Human Foods Program, tasked with overseeing the safety and labeling of dietary supplements, which are products intended to supplement the diet and contain one or more dietary ingredients (including vitamins, minerals, herbs or other botanicals, amino acids, and substances such as enzymes, organ tissues, glandulars, and metabolites).
The ODSP’s responsibilities are broad, encompassing the development and implementation of regulations, guidance documents, and enforcement actions. Its work directly impacts the billions of dollars spent annually by consumers on dietary supplements in the United States. The office plays a vital role in ensuring that these products are safe, manufactured according to good manufacturing practices, and accurately labeled. The emphasis on NDI regulation, compliance, and enforcement, as articulated by Dr. Oketch-Rabah, reflects the ongoing efforts to strengthen these fundamental aspects of dietary supplement oversight.
Broader Industry Implications and Future Outlook
The initiatives outlined by Dr. Oketch-Rabah carry significant implications for the entire dietary supplement industry, with a particular focus on botanical product manufacturers. The commitment to strengthening NDI regulations suggests a more rigorous review process for new ingredients, potentially requiring more comprehensive scientific data to support safety claims. This could lead to increased investment in research and development by companies seeking to introduce novel botanical ingredients.
The move to simplify labeling requirements for the DSHEA disclaimer, while beneficial for industry efficiency, also underscores the agency’s intention to focus on substance over strict adherence to form in certain areas. This pragmatic approach, if consistently applied, could foster greater trust and cooperation between the FDA and industry.
The embrace of AI and data analytics for oversight represents a significant technological leap. Companies that proactively adopt data-driven approaches to quality control, supply chain management, and consumer insights may find themselves better positioned to meet evolving regulatory expectations. Furthermore, the FDA’s emphasis on modernized oversight implies a future where regulatory actions may be informed by sophisticated data analysis, potentially leading to more targeted and effective interventions.
The overarching message from the ODSP, as delivered by Dr. Oketch-Rabah, is one of partnership and shared responsibility. The agency acknowledges that it cannot effectively regulate the complex dietary supplement market in isolation. By fostering open communication and collaboration, the FDA aims to build a more robust and trustworthy supplement ecosystem that benefits both industry and consumers. The coming years will likely see the continued implementation of these strategic priorities, with ongoing dialogue and adaptation expected as the FDA and the industry navigate the evolving landscape of dietary supplement regulation.
